Skip to main content Accessibility help
×
Home
Hostname: page-component-568f69f84b-4g88t Total loading time: 0.432 Render date: 2021-09-17T20:06:18.059Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": true, "newCiteModal": false, "newCitedByModal": true, "newEcommerce": true, "newUsageEvents": true }

Article contents

EPA-0294 – Can Alpha 1 Glycoproptein be Considered as a Marker of Negative Symptoms in Schizophrenia Patients?

Published online by Cambridge University Press:  15 April 2020

M. Henry-Benitez
Affiliation:
Department of Internal Medicine Dermatology and Psychiatry, School of Medicine, Santa Cruz de Tenerife, Spain
A. Morera-Fumero
Affiliation:
Department of Internal Medicine Dermatology and Psychiatry, School of Medicine, Santa Cruz de Tenerife, Spain
A. Henry-Gonzalez
Affiliation:
UDMFyC, University Hospital of the Canary Islands, Santa Cruz de Tenerife, Spain
A. Garcìa-Hernandez
Affiliation:
Plastic and Cosmetic Surgery Facility, Hospital Quirón, Santa Cruz de Tenerife, Spain
L. Fernandez-Lopez
Affiliation:
Department of Psychiatry, University Hospital of the Canary Islands, Santa Cruz de Tenerife, Spain
E. Diaz-Mesa
Affiliation:
Department of Psychiatry, University Hospital of the Canary Islands, Santa Cruz de Tenerife, Spain
S. Yelmo-Cruz
Affiliation:
Department of Psychiatry, University Hospital of the Canary Islands, Santa Cruz de Tenerife, Spain
C. Casariego-Ramìrez
Affiliation:
Department of Psychiatry, University Hospital of the Canary Islands, Santa Cruz de Tenerife, Spain
N. Suarez-Benitez
Affiliation:
Department of Psychiatry, University Hospital of the Canary Islands, Santa Cruz de Tenerife, Spain
R. Gracia-Marco
Affiliation:
Department of Psychiatry, University Hospital of the Canary Islands, Santa Cruz de Tenerife, Spain
J. Monzon-Diaz
Affiliation:
Department of Psychiatry, University Hospital of the Canary Islands, Santa Cruz de Tenerife, Spain
J.P. Girbau-Ronda
Affiliation:
Department of Psychiatry, University Hospital of the Canary Islands, Santa Cruz de Tenerife, Spain
Get access

Abstract

Introduction:

Recently, a renaissance of interest in ‘negative symptoms’ as emotional withdrawal or blunted affect, has occurred. Some investigators believe that these symptoms are important indicators of outcome, of response to treatment and of a distinct underlying pathologic process.

Research on the negative-symptom syndrome in schizophrenia has been handicapped until recently.

Aims:

This research aims at studying whether acute phase proteins, precisely, Alpha1-glycoprotein, can be considered as a marker of negativesymptom in Schizophrenia.

Methods:

29 chronic schizophrenics were assessed by the Positive and Negative Syndrome Scale (PANSS). A routine blood test including Alpha1-glycoprotein levels was carried out.

Results:

Alpha1-glycoprotein shows a positive correlation, according to Pearson correlation coefficient, with the Negative Scale at an almost significant level (p=.05), and at a significant level in the following items, Blunted affect (p=.03), Passive/apathetic Social Withdrawal (p=.01) of the Negative spectrum and Poor Attention (p=.02) of the General Psychopathology Scale.

Conclusions:

There is a significant correlation with two Negative variables and an almost significant one, spite of the small sample, with the Negative Scale. Further studies with bigger samples are needed in order to consider alpha1-glycoprotein as a schizophrenia negative psychopathology marker.

Type
EPW01 - Schizophrenia 1
Copyright
Copyright © European Psychiatric Association 2014

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)
Submit a response

Comments

No Comments have been published for this article.

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

EPA-0294 – Can Alpha 1 Glycoproptein be Considered as a Marker of Negative Symptoms in Schizophrenia Patients?
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

EPA-0294 – Can Alpha 1 Glycoproptein be Considered as a Marker of Negative Symptoms in Schizophrenia Patients?
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

EPA-0294 – Can Alpha 1 Glycoproptein be Considered as a Marker of Negative Symptoms in Schizophrenia Patients?
Available formats
×
×

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *